Oct 5 2010
Codexis, Inc. (Nasdaq: CDXS) today announced the expansion of its line of Codex® Panels with the introduction of Codex® Screening Kits.
The Codex® Screening Kits are developed from, and complement, the established Codex® Panels biocatalyst screening plates. Codex® Panels are used by more than 15 pharmaceutical and fine chemical companies worldwide, including Roche and Merck, to reduce pharmaceutical manufacturing process development time and costs.
They are being introduced this week at CPhI Worldwide, a global pharmaceutical ingredients convention in Paris.
Codexis custom biocatalysts have reduced process chemistry development times from months to weeks, increased manufacturing efficiency and lowered manufacturing costs for both development stage and commercial drugs. Codex® Panels have provided pharmaceutical process chemists access to a broad selection of Codexis custom enzymes which have been successfully used to develop processes for challenging manufacturing steps.
The new Codex® Screening Kits contain a selection of 24 of the top-performing enzymes from Codexis' extensive collection of biocatalyst variants. The Codex® Screening Kits are presented in a standard vial format to enhance ease of use for the process chemist, and were selected to deliver broad screening potential but with fewer enzymes than the Codex® Panels. The Codex® Panels were first introduced in 2007, and are now available representing five common enzyme classes. Codex® Screening Kits representing the two most commonly used enzyme classes, ketoreductase and transaminase enzymes, will be introduced this week.
"Codex® Panels were introduced nearly four years ago with Merck as our first customer. They have been widely adopted by pharmaceutical companies to improve manufacturing process development productivity," said Joseph Sarret, M.D., President, Codexis Pharmaceuticals Services & Enzyme Products. "The Codex® Screening Kits will enable our customers to incorporate this powerful technology more broadly throughout their development pipelines."
Source: http://www.codexis.com